Previous studies also revealed the risk of HBVr in patients with CHB after therapy with TNF-alpha inhibitors such as infliximab, supporting the role of TNF-alpha in viral replication suppression and the warrant of hepatitis B serological marker testing before the initiation of anti-TNF therapy [70,71]. Here, TNF is linked to hepatitis B virus infection.